In combination with WEE1 inhibition, impaired activity of the cell cycle checkpoint kinase and premature mitotic entry lead to an increase in DNA damage and apoptosis, making this combination a promising target for the treatment of acute myeloid leukemia (AML) [150]. The gene discussed is CHEK1; the disease is acute myeloid leukemia.